Furthermore, in a multicenter study involving metastatic melanoma patients with well-defined BRAF mutations, 856 individuals were selected to analyze BRAF mutation patterns, their response to MAPK pathway inhibitors, and survival outcomes. Here, BRAF is linked to metastatic melanoma.